Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Adaptimmune Therapeutics's profit margin for the twelve months ending Jun 30, 2025 was -260.8%. For fiscal 2024 it was -39.8%, against -188.9% the year before. The highest annual figure on record is -39.8% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -39.8% | +149.1 |
| FY2023 | Dec 31, 2023 | -188.9% | +420.6 |
| FY2022 | Dec 31, 2022 | -609.5% | +1961.5 |
| FY2021 | Dec 31, 2021 | -2571.0% | +715.8 |
| FY2020 | Dec 31, 2020 | -3286.8% | +8938.2 |
| FY2019 | Dec 31, 2019 | -12225.0% | −12064.5 |
| FY2018 | Dec 31, 2018 | -160.5% | +24.9 |
| FY2017 | Dec 31, 2017 | -185.4% | +38.1 |
| FY2015 | Jun 30, 2015 | -223.5% | +1182.7 |
| FY2014 | Jun 30, 2014 | -1406.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -221.8% | −276.0 |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -653.2% | +201.0 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -2303.4% | +18439.9 |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -43.1% | +580.0 |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | 54.2% | +471.2 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -854.2% | −856.4 |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -20743.3% | −20478.1 |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -623.0% | −31.9 |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -416.9% | +387.0 |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | 2.2% | +1408.2 |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -265.2% | +2477.0 |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -591.1% | +2933.5 |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -803.9% | +458.4 |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -1406.0% | +7295.1 |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -2742.3% | −304.7 |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -3524.6% | −554.6 |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -1262.3% | +4689.9 |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -8701.2% | −4999.8 |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -2437.6% | +1595.9 |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -2970.0% | +13613.1 |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -5952.2% | +20217.9 |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -3701.3% | −1255.5 |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -4033.5% | −4046.4 |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -16583.1% | −16098.0 |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -26170.1% | −25917.0 |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -2445.8% | −1807.3 |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | 12.9% | +16.1 |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -485.1% | +89.0 |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -253.0% | +509.4 |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | -638.5% | −115.0 |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | -3.2% | +68.1 |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | -574.1% | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | -762.4% | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -523.5% | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | -71.3% | – |
See a number that looks wrong?